Chaoqi Zhang1,2, Zhen Zhang1, Feng Li1, Zhibo Shen1,2, Yamin Qiao3, Lifeng Li1,2, Shasha Liu1,2, Mengjia Song1,2, Xuan Zhao1, Feifei Ren1,4, Qianyi He1, Bo Yang5, Ruitai Fan6, Yi Zhang1,2,4,7. 1. Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. 2. Cancer center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. 3. Department of Pediatrics, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. 4. School of Life Sciences, Zhengzhou University, Zhengzhou, Henan, 450052, China. 5. Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. 6. Department of Radiation Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. 7. Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan 450052, China.
Abstract
Background: B7-H3 is an immune checkpoint member that belongs to B7-CD28 families and plays a vital role in the inhibition of T-cell function. Importantly, B7-H3 is widely overexpressed on solid tumors, making it become an attractive target for cancer immunotherapy. To clarify the expression panel of B7-H3 in glioma, we explored the clinical and immune features of B7-H3 expression in a large-scale study. Methods and patients: Totally, 1323 glioma samples from Chinese Glioma Genome Atlas (CGGA) dataset, including 325 RNAseq data and 301 mRNA microarray data, and The Cancer Genome Atlas (TCGA) dataset, including 697 RNAseq data, were gathered into our research. The statistical analysis and graphical work were mainly realized by R language. Results: B7-H3 expression was found positively correlated with the grade of malignancy, which might be caused by hypomethylation. The expression level of B7-H3 was consistently up-regulated in IDH wild-type glioma and highly enriched in mesenchymal subtype. GSEA analysis suggested that B7-H3 related genes were more involved in immune response and angiogenesis in glioma. Moreover, B7-H3 showed a consistent positive relationship with stromal and immune cell populations. Further analysis confirmed that B7-H3 played an important role in T-cell-mediated immunity, especially in T-cell-mediated immune response to tumor cell. Circos plots revealed that B7-H3 was tightly associated with most B7 members and other immune checkpoints. Univariate and multivariate cox analysis demonstrated that B7-H3 was an independent prognosticator for glioma patients. Conclusion: B7-H3 represents the malignant phenotype of glioma and independently predicted worse prognosis in glioma patients. Moreover, B7-H3 collaborating with other checkpoint members may contribute to the dysfunctional phenotype of T cell. These findings will be helpful for further optimizing immunotherapies for glioma.
Background: B7-H3 is an immune checkpoint member that belongs to B7-CD28 families and plays a vital role in the inhibition of T-cell function. Importantly, B7-H3 is widely overexpressed on solid tumors, making it become an attractive target for cancer immunotherapy. To clarify the expression panel of B7-H3 in glioma, we explored the clinical and immune features of B7-H3 expression in a large-scale study. Methods and patients: Totally, 1323 glioma samples from Chinese Glioma Genome Atlas (CGGA) dataset, including 325 RNAseq data and 301 mRNA microarray data, and The Cancer Genome Atlas (TCGA) dataset, including 697 RNAseq data, were gathered into our research. The statistical analysis and graphical work were mainly realized by R language. Results:B7-H3 expression was found positively correlated with the grade of malignancy, which might be caused by hypomethylation. The expression level of B7-H3 was consistently up-regulated in IDH wild-type glioma and highly enriched in mesenchymal subtype. GSEA analysis suggested that B7-H3 related genes were more involved in immune response and angiogenesis in glioma. Moreover, B7-H3 showed a consistent positive relationship with stromal and immune cell populations. Further analysis confirmed that B7-H3 played an important role in T-cell-mediated immunity, especially in T-cell-mediated immune response to tumor cell. Circos plots revealed that B7-H3 was tightly associated with most B7 members and other immune checkpoints. Univariate and multivariate cox analysis demonstrated that B7-H3 was an independent prognosticator for gliomapatients. Conclusion:B7-H3 represents the malignant phenotype of glioma and independently predicted worse prognosis in gliomapatients. Moreover, B7-H3 collaborating with other checkpoint members may contribute to the dysfunctional phenotype of T cell. These findings will be helpful for further optimizing immunotherapies for glioma.
Entities:
Keywords:
B7-H3; CGGA, Chinese Glioma Genome Atlas; CNS, central nervous system; GBM, glioblastoma; HPA, Human Protein Atlas; IDH, isocitrate dehydrogenase; OS, overall survival; TCGA, The Cancer Genome Atlas; glioma; immune checkpoint; immunotherapy; prognosis
Authors: Roberta Castriconi; Alessandra Dondero; Raffaella Augugliaro; Claudia Cantoni; Barbara Carnemolla; Angela Rita Sementa; Francesca Negri; Romana Conte; Maria Valeria Corrias; Lorenzo Moretta; Alessandro Moretta; Cristina Bottino Journal: Proc Natl Acad Sci U S A Date: 2004-08-16 Impact factor: 11.205
Authors: Michael Prosniak; Larry A Harshyne; David W Andrews; Lawrence C Kenyon; Kamila Bedelbaeva; Tatiyana V Apanasovich; Ellen Heber-Katz; Mark T Curtis; Paolo Cotzia; D Craig Hooper Journal: Clin Cancer Res Date: 2013-06-05 Impact factor: 12.531
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Steven Seaman; Zhongyu Zhu; Saurabh Saha; Xiaoyan M Zhang; Mi Young Yang; Mary Beth Hilton; Karen Morris; Christopher Szot; Holly Morris; Deborah A Swing; Lino Tessarollo; Sean W Smith; Sylvia Degrado; Dmitry Borkin; Nareshkumar Jain; Julia Scheiermann; Yang Feng; Yanping Wang; Jinyu Li; Dean Welsch; Gary DeCrescenzo; Amit Chaudhary; Enrique Zudaire; Kimberly D Klarmann; Jonathan R Keller; Dimiter S Dimitrov; Brad St Croix Journal: Cancer Cell Date: 2017-04-10 Impact factor: 31.743
Authors: Kosuke Yoshihara; Maria Shahmoradgoli; Emmanuel Martínez; Rahulsimham Vegesna; Hoon Kim; Wandaliz Torres-Garcia; Victor Treviño; Hui Shen; Peter W Laird; Douglas A Levine; Scott L Carter; Gad Getz; Katherine Stemke-Hale; Gordon B Mills; Roel G W Verhaak Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: Jinhua Wang; Kelly K Chong; Yoshitaka Nakamura; Linhda Nguyen; Sharon K Huang; Christine Kuo; Wang Zhang; Hua Yu; Donald L Morton; Dave S B Hoon Journal: J Invest Dermatol Date: 2013-03-08 Impact factor: 8.551
Authors: Ahmed M Mahmoud; Igor Frank; Jacob J Orme; Roxane R Lavoie; Prabin Thapa; Brian A Costello; John C Cheville; Sounak Gupta; Haidong Dong; Fabrice Lucien Journal: BMC Urol Date: 2022-06-24 Impact factor: 2.090
Authors: Johnny Duerinck; Julia Katharina Schwarze; Gil Awada; Jens Tijtgat; Freya Vaeyens; Cleo Bertels; Wietse Geens; Samuel Klein; Laura Seynaeve; Louise Cras; Nicky D'Haene; Alex Michotte; Ben Caljon; Isabelle Salmon; Michaël Bruneau; Mark Kockx; Sonia Van Dooren; Anne-Marie Vanbinst; Hendrik Everaert; Ramses Forsyth; Bart Neyns Journal: J Immunother Cancer Date: 2021-06 Impact factor: 13.751